Arrowhead Research announced this week that it has signed a RNAi services agreement with Germany's Axolabs, bringing together the US and European halves of Roche's former RNA therapeutics operations that were divested by the biopharmaceutical giant in 2010.

Under the terms of the deal, Axolabs will provide Arrowhead and its partners with oligonucleotide optimization, synthesis, and analytic services. These specifically include siRNA design; lead identification, optimization, and characterization; and siRNA synthesis.

Additional terms were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.